Phase II study of <sup>90</sup>Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma

Izidore Lossos, Jesus C. Fabregas, Tulay Sengul, Feng Miao, Deborah Goodman, Aldo N Serafini, Peter Hosein, Alexandra Stefanovic, Joseph D Rosenblatt, James E Hoffman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with <sup>90</sup>yttrium (<sup>90</sup>Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6-97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9-59.5%) and 5-year OS was 71.8% (90% CI: 46.8-86.5%). Overall, <sup>90</sup>Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.

Original languageEnglish (US)
Pages (from-to)1750-1755
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Disease-Free Survival
Lymphoma
Confidence Intervals
Radioimmunotherapy
Survival
Therapeutics
Survival Rate
Safety
ibritumomab tiuxetan

Keywords

  • <sup>90</sup>Y ibritumomab tiuxetan
  • Marginal zone lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phase II study of <sup>90</sup>Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. / Lossos, Izidore; Fabregas, Jesus C.; Sengul, Tulay; Miao, Feng; Goodman, Deborah; Serafini, Aldo N; Hosein, Peter; Stefanovic, Alexandra; Rosenblatt, Joseph D; Hoffman, James E.

In: Leukemia and Lymphoma, Vol. 56, No. 6, 01.06.2015, p. 1750-1755.

Research output: Contribution to journalArticle

@article{412e25197bc2448e9f12affcbd78f9d1,
title = "Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma",
abstract = "The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with 90yttrium (90Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81{\%} with advanced-stage disease and 44{\%} with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5{\%} (90{\%} confidence interval [CI]: 65.6-97.7{\%}), including a complete response in eight (50{\%}), complete response unconfirmed in one (6{\%}) and partial response in five (31{\%}) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40{\%} (90{\%} CI: 19.9-59.5{\%}) and 5-year OS was 71.8{\%} (90{\%} CI: 46.8-86.5{\%}). Overall, 90Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.",
keywords = "<sup>90</sup>Y ibritumomab tiuxetan, Marginal zone lymphoma, Radioimmunotherapy",
author = "Izidore Lossos and Fabregas, {Jesus C.} and Tulay Sengul and Feng Miao and Deborah Goodman and Serafini, {Aldo N} and Peter Hosein and Alexandra Stefanovic and Rosenblatt, {Joseph D} and Hoffman, {James E}",
year = "2015",
month = "6",
day = "1",
doi = "10.3109/10428194.2014.975801",
language = "English (US)",
volume = "56",
pages = "1750--1755",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma

AU - Lossos, Izidore

AU - Fabregas, Jesus C.

AU - Sengul, Tulay

AU - Miao, Feng

AU - Goodman, Deborah

AU - Serafini, Aldo N

AU - Hosein, Peter

AU - Stefanovic, Alexandra

AU - Rosenblatt, Joseph D

AU - Hoffman, James E

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with 90yttrium (90Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6-97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9-59.5%) and 5-year OS was 71.8% (90% CI: 46.8-86.5%). Overall, 90Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.

AB - The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with 90yttrium (90Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6-97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9-59.5%) and 5-year OS was 71.8% (90% CI: 46.8-86.5%). Overall, 90Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.

KW - <sup>90</sup>Y ibritumomab tiuxetan

KW - Marginal zone lymphoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84932097226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932097226&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.975801

DO - 10.3109/10428194.2014.975801

M3 - Article

C2 - 25315074

AN - SCOPUS:84932097226

VL - 56

SP - 1750

EP - 1755

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -